Anavex Life Sciences Corp. (AVXL) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Anavex Life Sciences Corp. (AVXL) closed at USD 1.48 on 2026-10-15, a change of -81.5 % over the past year, with a market capitalization of USD 121.43M.

Anavex Life Sciences Corp. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Anavex Life Sciences Corp. key figures

Previous close

USD 1.48 (2026-10-15)

1-year change

-81.5 %

Market cap

USD 121.43M

Enterprise value

USD 3.11M

P/E ratio (trailing)

-9.36

P/E ratio (forward)

-2.38

EPS (trailing)

-0.14

EPS (forward)

-0.55

PEG ratio

n/a

Price to book

1.08

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

16.63

Employees

34

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Anavex Life Sciences Corp. and compare it with other stocks.